Outlook Therapeutics, Inc. 8K

Outlook Therapeutics received FDA approval for LYTENAVA as the first ophthalmic bevacizumab for wet AMD and is initiating its U.S. commercial launch with anticipated 12‑year market exclusivity.

On July 24, 2026, Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration approved LYTENAVA (bevacizumab‑vikg), the first and only FDA‑approved ophthalmic bevacizumab for the treatment of neovascular age‑related macular degeneration (wet AMD), granting the company an anticipated 12 years of market exclusivity under the Biologics Price Competition and Innovation Act and enabling the launch of a new commercial retina franchise targeting the approximately $8.5 billion U.S. anti‑VEGF retina market, with product availability expected for eligible U.S. patients before year‑end.

Filing Facts

CIK

1649989

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-086685

Alert Tier

8